Swiss fine and specialty chemicals producer Lonza has expanded its mammalian production capacity to meet increased demand for biopharmaceutical development and clinical manufacturing services.

Two 1,000 liter single-use bioreactors have been added to its site in Slough, UK, the company’s center of excellent for development and clinical supply, significantly increasing capacity.

Lonza said the new reactors, equipped with controllers that enable parallel operations and expanded process capabilities with flexible operating scales and bioreactor types, complement existing single-use equipment for both seed train systems and downstream processing, including chromatography, filtration and ultrafiltration unit operations.

The company added that the technologies support its ability to accommodate a variety of customer projects and processes across scales and clinical phases.